Joke A. Bouwstra

Joke A. Bouwstra


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
JBJoke A. Bouwstra
Joke A. Bouwstra
MPMaria Ponec
Maria Ponec

1 January 2003 in Progress in Lipid Research
Verified
Journal Article
Closed access
JBJoke A. Bouwstra
Joke A. Bouwstra

1 March 2014 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
JSJ. van Smeden
J. van Smeden
MJM. Janssens
M. Janssens
GGG.S. Gooris
G.S. Gooris
JBJoke A. Bouwstra
Joke A. Bouwstra

1 December 2012 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MJMichelle Janssens
Michelle Janssens
JSJeroen van Smeden
Jeroen van Smeden
GGGert S. Gooris
Gert S. Gooris
WBWim Bras
Wim Bras
GPGuiseppe Portale
Guiseppe Portale
JBJoke A. Bouwstra
Joke A. Bouwstra
A hallmark of atopic eczema (AE) is skin barrier dysfunction. Lipids in the stratum corneum (SC), primarily ceramides, fatty acids, and cholesterol, are crucial for the barrier function, but their role in relation to AE is indistinct. Filaggrin is an epithelial barrier protein with a central role in the pathogenesis of AE. Nevertheless, the precise causes of AE-associated barrier dysfunction are largely unknown. In this study, a comprehensive analysis of ceramide composition and lipid organization in nonlesional SC of AE patients and control subjects was performed by means of mass spectrometry, infrared spectroscopy, and X-ray diffraction. In addition, the skin barrier and clinical state of the disease were examined. The level of ceramides with an extreme short chain length is drastically increased in SC of AE patients, which leads to an aberrant lipid organization and a decreased skin barrier function. Changes in SC lipid properties correlate with disease severity but are independent of filaggrin mutations. We demonstrate for the first time that changes in ceramide chain length and lipid organization are directly correlated with the skin barrier defects in nonlesional skin of AE patients. We envisage that these insights will provide a new therapeutic entry in therapy and prevention of AE.

1 July 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MDMogbekeloluwa O. Danso
Mogbekeloluwa O. Danso
VDVincent van Drongelen
Vincent van Drongelen
AMAat Mulder
Aat Mulder
JEJeltje van Esch
Jeltje van Esch
HSHannah Scott
Hannah Scott
JBJoke A. Bouwstra
Joke A. Bouwstra

1 March 2005 in Drug Discovery Today: Technologies
Verified
Journal Article
Closed access
PHP. Loan Honeywell-Nguyen
P. Loan Honeywell-Nguyen
JBJoke A. Bouwstra
Joke A. Bouwstra